Bartlett HIV/AIDS Review: September 15, 2004 Dr. Bartlett reviews the latest data on TDF vs d4T, FTC vs d4T, EFV vs ATZ, hyperlactatemia after NRTI switch, HAART and sexual risk-taking, cancer risk ...
Antiretroviral therapy has decreased the risk of lymphoma in the HIV-positive patient population, yet the incidence is still approximately 70-times greater than the incidence in the noninfected ...
A cellular protein that helps guide immune cells to the gut has been newly identified as a target of HIV when the virus begins its assault on the body's immune system, according to researchers from ...
Roger Paredes, MD, PhD, is Head of the Infectious Diseases Department, Hospital Germans Trias i Pujol and Principal Investigator of the Microbial Genomics Group at the IrsiCaixa AIDS Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback